UroGen Pharma/URGN

$14.53

1.11%
-
1D1W1MYTD1YMAX

About UroGen Pharma

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Ticker

URGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Elizabeth Barrett

Employees

198

Headquarters

Ra'anana, Israel

UroGen Pharma Metrics

BasicAdvanced
$490.33M
Market cap
-
P/E ratio
-$3.72
EPS
1.08
Beta
-
Dividend rate
$490.33M
1.07584
$24.13
$8.69
373.19K
5.421
5.239
-5.43%
-65.14%
-79.01%
5.928
28.52%
22.69%
91.39%

What the Analysts think about UroGen Pharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
164.97% upside
High $54.00
Low $18.00
$14.53
Current price
$38.50
Average price target

UroGen Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-110.63% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$23.5M
12.98%
Net income
$-26M
19.27%
Profit margin
-110.63%
5.56%

UroGen Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.88%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.30
-$1.03
-$0.68
-$0.72
-
Expected
-$1.33
-$1.14
-$0.85
-$0.68
-$0.87
Surprise
-2.26%
-9.33%
-19.62%
5.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for UroGen Pharma stock?

UroGen Pharma (URGN) has a market cap of $490.33M as of April 25, 2024.

What is the P/E ratio for UroGen Pharma stock?

The price to earnings (P/E) ratio for UroGen Pharma (URGN) stock is 0 as of April 25, 2024.

Does UroGen Pharma stock pay dividends?

No, UroGen Pharma (URGN) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next UroGen Pharma dividend payment date?

UroGen Pharma (URGN) stock does not pay dividends to its shareholders.

What is the beta indicator for UroGen Pharma?

UroGen Pharma (URGN) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the UroGen Pharma stock price target?

The target price for UroGen Pharma (URGN) stock is $38.5, which is 170.94% above the current price of $14.21. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell UroGen Pharma stock

Buy or sell UroGen Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing